10-12 September 2018 //  Lancaster Royal Hotel, London


Cenk Sumen

Dr Cenk Sumen

Senior Manager, Business Development, PCT, a Caladrius Company

Cenk Sumen’s love of T cells began with his PhD project, where he developed an artificial membrane system for deconstructing the molecular events in T cell antigen recognition. During his postdoc he developed a new molecular tool using quantum dots to track virus antigens in vivo. Since then he has held technical, marketing, sales, and business development positions at Memorial Sloan Kettering Cancer Center, Life Technologies, STEMCELL Technologies, PerkinElmer and more. [PhD, Stanford University School of Medicine; postdoc, Harvard University]


Key Publications:

• Grakoui A, et al. The immunological synapse: a molecular machine controlling T cell activation. Science. 1999; 285:221-227

• Sumen C, et al. T cell receptor antagonism interferes with MHC clustering and integrin patterning during immunological synapse formation. Journal of Cell Biology. 2004; 166:579-90.

• Sumen C, et al. Adoptive T-cell therapies: Unlocking the potential of engineered antigen receptors. Drug Discovery World. 2015; 16(2): 47-54.


2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad